The survival rates of many cancers have significantly improved due to recent advancements
in cancer screening and therapeutics. Although better cancer outcomes are encouraging …

The Oncology Grand Rounds series is designed to place original reports published in the
Journal into clinical context. A case presentation is followed by a description of diagnostic …

Aims Cancer survivors have a greater risk of cardiovascular disease (CVD). Although Life's
Simple 7 is used for CVD risk stratification in a general population, its utility in cancer …

Purpose This study aimed to examine the potential benefit of sodium-glucose cotransporter
2 (SGLT2) inhibitors for patients with metabolic dysfunction-associated fatty liver disease …

The first part of this review highlighted the evolving landscape of atherosclerosis, noting
emerging cardiometabolic risk factors, the growing impact of exposomes, and social …

Although several randomized clinical trials have reported the potential benefit of sodium-
glucose cotransporter 2 inhibitors (SGLT2i) in reducing blood pressure (BP), whether …

Background Metabolic dysfunction-associated fatty liver disease (MAFLD) is a novel concept
of hepatic disease. Although the prevalences of heart failure (HF) and atrial fibrillation (AF) …

We sought to clarify the incidence of major adverse cardiac events (MACE) after the initiation
of immune checkpoint inhibitors (ICIs). We analyzed the JMDC Claims Database between …

Background and aims Although the importance of hypertension in patients with cancer is
widely recognized, little is known about the risk of develo** hypertension in patients with a …

Objective To investigate the association between body mass index (BMI) changes and the
risk of cardiovascular disease (CVD) in patients with cancer. Patients and Methods This …